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j ou rna l homepage: ht tp : / /www. journa ls .e lsev ie r .com/genomics-data /Data collaboration will lead precision medicineI was excited when Bart Wacek, a publisher at Elsevier, approached
me several years ago to discuss creating a ‘big data’ journal. At the
time I was at Illumina getting ready to launch BaseSpace and believed
strongly that storing data centrally and driving universal reporting for-
mats would help to both democratize access and promote innovation. I
still do.
The timing of Genomics Data could not be better. Today the brightest
minds coming out of top undergraduate and graduate programs are
going into data-driven ﬁelds. Out here in Silicon Valley anybody who
can correctly spell “machine learning” or “Bayesian” is practically guar-
anteed a job, if not venture funding. As DJ Patil, formerly of LinkedIn
fame and now with big data startup RelateIQ has noted, there are
today more data jobs posted on LinkedIn (61,000) than engineering
jobs (53,000) [1]. That numerous institutions have begun offering data
science curriculum is no coincidence, and suggests the trend is here to
stay [2].
This bodes well for genomics in general, and in particular for the di-
agnosis and treatment of disease. As the genome research discipline has
matured, the core analytical tools that were once centralized at genome
institutes and leading academic medical centers (AMCs) have become
ubiquitous, much to the credit of those organizations. This has freed ac-
ademic andmedical practitioners fromdeveloping tools and has instead
shifted the analytical focus to where it ought to be: the patient.
Of course, tools are important. A surgeon wouldn't be able to per-
form surgery without a scalpel, and the same holds for building a better
de novo assembler, a faster aligner, or a more intuitive variant interpre-
tation engine all to gain insight from raw data. But focusing on building
the best scalpel won't transform theway a surgeon treats her patient, or
help her to determine whether surgery might be avoided in the ﬁrst
place. To deliver innovation thatwill guide those decisions, private com-
panies, hospitals, and AMCs are starting to use ‘omics’ data both in clin-
ical research and at the point of care. They are doing so by leveraging
complex datasets to determine what tests to order next, what courses
of treatment to administer to a patient, and how similar patients
responded to that treatment course (how we deﬁne “similar” here is
an interesting discussion in and of itself).
Recent technological and clinical advances suggest that a transition
from research to mainstream is underway. A harbinger for this was a
study just published out of the Mother Infant Research Institute at
Tufts University that used massively parallel sequencing to detect fetal
chromosome abnormalities an order-of-magnitude more accurately
than the current standard of care [3]. With the cost of sequencing con-
tinuing to decline, these early successes will lead the way to standard-
ized clinical sequencing across a range of diseases [4].http://dx.doi.org/10.1016/j.gdata.2014.04.001
2213-5960/© 2014 The Author. Published by Elsevier Inc. This is an open access article under tUndoubtedly the data challenges will shift as our understanding of
the genome matures and a greater importance is placed on integrating
multiple ‘omics’ data with an assortment of clinical indicators. Things
like family health history, symptoms, medications, pathology reports,
and patient outcomes can be as important to an accurate diagnosis
and treatment as the underlying genetic makeup [5]. As the power of
a wider breadth of data is realized, the network that results from nu-
merous institutions sharing data across a range of diseases will have
large statistics to drive insight [6]. The data challenge will be different
but no less complex.
This will not simply happen on its own; hospitals, diagnostic labs and
clinical researchers will need to actively collaborate. And yet, a very seri-
ous public discussion is underway about the acceptable use of data and
how best to protect individuals from unintended consequences. Is it OK
to collect and report metadata (this data exists in a clinical setting just
as it does when we surf the web at home)? If data technology makes a
mistake in how it analyzes or reports an individual's information, how
do we ﬁx the technology and how do we correct the public record?
Data has come under a heightened level of scrutiny in all aspects of
life, and that's important. But rather than shy away from the debate
we can step forward and responsibly support a collaborative paradigm.
Our ability to realize the potential of precision medicine is at stake, and
open access forums like Genomics Data will need to stay vigilant of the
changing data landscape to provide platforms and formats that are as
relevant tomorrow as they seem today.
After all, great young minds are counting on it.
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